A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc., a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases.
Merck, known as MSD outside the United States and Canada, and the Institute for Systems Biology (ISB), announced a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines.
Affinia Therapeutics has signed a research collaboration deal worth more than $1.6bn with Vertex Pharmaceuticals to discover and develop adeno-associated virus capsids (AAV capsids) to be used in the latter's genetic therapies aimed at treating people with serious diseases.
Affinivax, a clinical stage biotechnology company with its novel MAPS technology platform for vaccines and immunotherapies, today announced the completion of a $120 million Series B financing round, led by Viking Global Investors with participation from Bain Capital Life Sciences and Ziff Capital Partners.
Agastiya Biotech announces it has discovered its previously tested anti-cancer small molecule AB001 as a viable SARS-CoV-2 virus therapeutic.
Gilead Sciences and its subsidiary Kite have joined forces with oNKo-innate to discover and develop cancer immunotherapies focused on natural killer (NK) cells.
Revive Therapeutics has engaged Complete Phytochemical Solutions, which specialises in unique and complex analyses and formulation development of phytochemicals, to advance the Company’s research and development initiatives of psilocybin-based products for the pharmaceutical market.
The Kluyver Center for Genomics of Industrial Fermentation in Delft, Holland, is a consortium of several different Universities and Research Centres.
LegoChem Biosciences, based in Daejeon, South Korea, announced today that it has entered a research collaboration and license agreement with Iksuda Therapeutics (“Iksuda”) for the development of antibody-drug conjugates in oncology.
Starpharma announced that its proprietary VivaGel active, astodrimer sodium (SPL7013), has been shown in laboratory studies to have significant antiviral activity against the coronavirus that causes COVID-19 (coronavirus disease).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.